Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors.

ABSTRACT: Gastrointestinal stromal tumors represent the most common mesenchymal tumor of the digestive tract, driven by gain-of-function mutations in KIT. Despite its proven benefits, half of the patients treated with imatinib show disease progression within 2 years due to secondary resistance mutations in KIT. It remains unclear how the genomic and transcriptomic features change during the acquisition of imatinib resistance. Here, we performed exome sequencing and microarray transcription analysis for four imatinib-resistant cell lines and one cell line briefly exposed to imatinib. We also performed exome sequencing of clinical tumor samples. The cell line briefly exposed to imatinib exhibited few single-nucleotide variants and copy-number alterations, but showed marked upregulation of genes relate

SUBMITTER: Takahashi T 

PROVIDER: S-EPMC5324566 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature